Company Encyclopedia
View More
name
Longeveron
LGVN.US
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
1.875 T
LGVN.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking311/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-119.92%E
    • Profit Margin-1485.11%E
    • Gross Margin91.24%A
  • Growth ScoreD
    • Revenue YoY-22.41%E
    • Net Profit YoY19.68%B
    • Total Assets YoY-47.99%E
    • Net Assets YoY-61.11%E
  • Cash ScoreD
    • Cash Flow Margin-6.73%D
    • OCF YoY-22.41%E
  • Operating ScoreE
    • Turnover0.06E
  • Debt ScoreB
    • Gearing Ratio35.94%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Longeveron Highlights Laromestrocel Data Showing Reduced Brain Neuroinflammation in Mild Alzheimer’s Disease

    Longeveron Inc. will present data from its CLEAR MIND study on laromestrocel's effects on brain neuroinflammation in mild Alzheimer's disease at the CTAD 2025 conference. The presentation will occur from December 1-4, 2025, in San Diego, California. The findings have not yet been disclosed.

    Reuters·
    US
    LGVN
    -1.82%
    Reuters·
    US
    LGVN
    -1.82%

    Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty

    Longeveron Inc. has been granted a U.S. patent for its mesenchymal stem cell therapy aimed at treating aging-related frailty. The patent, valid until 2038, covers the use of isolated allogeneic MSCs to alleviate symptoms like weakness and exhaustion in older patients. The company's lead therapy, laromestrocel, has shown promising results in two clinical trials focused on this condition.

    Reuters·
    US
    LGVN
    -1.82%
    Reuters·
    US
    LGVN
    -1.82%

    Longeveron Announces Resignation of Board Members

    Longeveron Inc. announced the immediate resignation of Board members Mr. Khoso Baluch and Ms. Neha Motwani, effective November 7, 2025. Their resignations were not due to disagreements with the company. The current analyst rating for Longeveron (LGVN) stock is a Hold with a price target of $0.50. Spark's AI Analyst rates LGVN as Neutral, citing significant financial challenges, declining revenues, and negative profitability, despite some positive developments in clinical trials. The company's market cap is $15.82M with bearish technical sentiment.

    Tip Ranks·
    US
    LGVN
    -1.82%
    Tip Ranks·
    US
    LGVN
    -1.82%

    Longeveron: Promising Outlook with Clinical Progress and Strategic Adjustments

    Michael Okunewitch from Maxim Group maintains a Buy rating on Longeveron with a price target of $4.00, citing progress in clinical trials and potential catalysts. The ELPIS II trial for hypoplastic left heart syndrome has completed enrollment, with pivotal results expected in Q3 2026. A positive outcome could lead to approval filing. Favorable regulatory conditions and strategic adjustments, including cost optimization and funding efforts, enhance the outlook. Roth MKM also reiterated a Buy rating with a $3.00 target.

    Tip Ranks·
    US
    LGVN
    -1.82%
    Tip Ranks·
    US
    LGVN
    -1.82%

    Longeveron Inc. Earnings Call: Mixed Sentiments Amid Clinical Progress

    Longeveron Inc.'s recent earnings call revealed mixed sentiments regarding its clinical progress and financial challenges. While the company has advanced in its HLHS clinical trial and received favorable FDA designations, it faces a 53% revenue decline and increased expenses, leading to a 45% rise in net loss. The company is seeking partnerships and additional funding to navigate its financial risks, with cash expected to last until late Q1 2026. A delay in the BLA filing for HLHS is now anticipated in 2027, despite positive initial results in multiple trials.

    Tip Ranks·
    US
    LGVN
    -1.82%
    Tip Ranks·
    US
    LGVN
    -1.82%